I[ntroduction]{.smallcaps} {#sec1-1}
==========================

The neurotoxin called botulinum toxin (BT) is produced by the bacterium *Clostridium botulinum*. This toxin is capable of causing muscle paralysis by blocking the release of Ach at the neuromuscular (NM) junction of striated muscle. Among the several types of BT, subtype A (Botox, Allergan, Inc., Irvine, CA, USA) is the most potent toxin produced by the bacterium.\[[@ref1]\] The basis of botulinum neurotoxin therapy is the localized inhibition of exocytosis from selected neurons after the toxin has been injected into specific target areas such as muscles. The local route of administration along with the specific features of the neurotoxin formulation results in such properties.\[[@ref2]\] The BT Type A (BT-A) is a purified protein which causes partial paralysis when injected into a muscle, thereby reducing spasticity and muscle stiffness.

S[tructural]{.smallcaps} A[spects of]{.smallcaps} B[otulinum]{.smallcaps} T[oxin]{.smallcaps} {#sec1-2}
=============================================================================================

The seven different serotypes of BT known today are A, B, C1, D, E, F, and G. Till now only serotype A was available for commercial use in the forms of Botox (Allergan, Inc., Irvine, CA, USA) and Dysport (Ipsen Ltd., Slough, Berkshire).\[[@ref3]\]

BT is synthesized as a single chain (150 kd) and subsequently cleaved into a di-chain molecule with a disulfide bridge. The light chain acts as a zinc endopeptidase with proteolytic activity located at the N-terminal end \[[Figure 1](#F1){ref-type="fig"}\]. The heavy chain provides cholinergic specificity and binding of the toxin to presynaptic receptors. This promotes translocation of the toxin across the endosomal membrane. Despite having different antigenic properties, the serotypes of BT are found to exhibit similar structure within themselves.

![Structure of botulinum toxin](NJMS-7-10-g001){#F1}

A single-chain inactive 150 kDa protein is formed during BT synthesis which is found to be bound to the nontoxic proteins as a complex. This prevents BT from damage when ingested in oral botulism poisoning.\[[@ref4]\]

M[echanism of]{.smallcaps} A[ction of]{.smallcaps} B[otulinum]{.smallcaps} T[oxin]{.smallcaps} {#sec1-3}
==============================================================================================

Botulinum neurotoxin prevents the release of Ach at the presynaptic NM junction thereby inducing flaccid paralysis. This toxin-mediated paralysis includes three principal steps: binding, internalization, and inhibition of the release of neurotransmitter.\[[@ref5]\] BT acts locally in the peripheral nervous system by blocking the release of Ach in the presynaptic NM junction. In contrast, the tetanus toxin migrates retrograde into the central nervous system from the same presynaptic NM junction to affect the interneurons in the spinal cord from releasing glycine and g-amino-butyric acid. At the presynaptic terminal, the cleavage of synaptosome-associated protein (SNAP-25) takes place by serotypes A, C, and E, but only serotype C primarily affects the protein syntaxin also. The other BT serotypes B, D, F, and G affects the cleavage of vesicle-associated membrane protein. BT results in reversible denervation atrophy at the NM junction after two important phases: (1) An initial phase in which sprouting of non-collateral axons occur. (2) Development of a new functional NM junction at the incipient nerve terminals, thus replacing the original motor endplate. It takes about 3 months for the new terminals to regress and the parent terminal to reestablish its functional core.\[[@ref3]\]

P[harmacology of]{.smallcaps} B[otulinum]{.smallcaps} N[eurotoxins]{.smallcaps} {#sec1-4}
===============================================================================

The two different marketed brands for BT-A, namely Botox and Dysport have remarkably different potencies. One unit of Botox is considered to be equivalent to approximately 3--4 units of Dysport\[[@ref6]\] though there remains a controversy for the precise conversion. Electromyographic data measurement has been done in human patients to evaluate the duration of Botox and Myobloc on opposite extensor digitorum muscles.\[[@ref7]\] The BT-A has been in therapeutic use since the late 1970s\[[@ref8]\] and has been recognized for its remarkable safety profile. The mainstay of therapy is the injectable form and it is also significantly highly safer than the oral pharmacologic version of the toxin.\[[@ref9]\] It is evident that only a localized effect is produced by the injectable form even in clinical conditions requiring larger injection amounts (e.g., for cervical dystonia).\[[@ref10]\] Stability of the toxin is a prominent concern for clinical use. During the manufacturing process of BT-A, lyophilization or vacuum drying is important for direct impact on the activity of the toxin and denaturation of proteins. This leads to formation of antibody without any beneficial clinical efficiency. The reconstitution of BT-A with saline makes the pH of the solution 7.3. At this neutral pH, there is rapid loss of its clinical efficacy within 12 h despite refrigeration. In contrast, BT-B complex undergoes extreme adverse conditions during its production but still manages to remain intact and highly purified.\[[@ref11]\]

I[ndications of]{.smallcaps} B[otulinum]{.smallcaps} T[oxin]{.smallcaps} {#sec1-5}
========================================================================

Facial rejuvenation {#sec2-1}
-------------------

### Forehead rhytids {#sec3-1}

Transverse rhytids in the forehead region are treated by directly injecting BT in the frontalis muscles. Successful rejuvenation of the rhytids requires relaxation of the frontalis muscles but usually associated with subsequent brow ptosis through the unopposed depressor activity of the procerus, orbicularis oculi, and corrugator muscles.

### Glabellar rhytids {#sec3-2}

The injection of Botox in procerus and corrugators muscles respectively successfully resulted in the relaxation of transverse and vertical rhytids lying between the brows in the glabellar regions. This method helps to minimize the possible diffusion through the orbital septum that causes eyelid ptosis, thus achieving maximum effect. Since procerus and corrugators muscles act as brow depressors, a treatment of the entire glabella appropriately with Botox chemodenervation can achieve a slight medial brow elevation.

### Crow\'s feet {#sec3-3}

It is generally the action of underlying orbicularis oculi muscle that results into lateral orbital rhytids, or crow\'s feet. The repeated squinting or blinking cause excessive muscular activity, thus leads to pleating of the overlying skin in a radial fashion from the lateral canthus and orbital rim.\[[@ref12]\]

### Marionette lines {#sec3-4}

In the perioral region, the vertical lines found at the oral commissures are called the classic "marionette lines," or melomental rhytids that give the impression of sadness or disapproval.

### Vertical lip rhytids {#sec3-5}

It is the persistent, repetitive contraction of the orbicularis oris muscle that leads to the development of vertical rhytids of the upper and lower lip. These wrinkles are named as smoker\'s lines as these are more frequently observed in individuals who smoke. An overaggressive treatment usually results in lip asymmetry and possible speech or drinking impairment. A better treatment for these rhytids is the skin resurfacing technique, such as with chemical peels or a CO~2~ laser treatment.

### Mentalis crease {#sec3-6}

A long-term hyperfunctioning mentalis muscle develops a deep transverse crease in the mentum. The origin of mentalis muscle lies in the mentum inferior to the incisor fossa and extends vertically medially to fuse with the orbicularis oris.\[[@ref13]\]

### Neck bands {#sec3-7}

During aging, the platysma separates in the midline anteriorly causing the overlying skin loses its elasticity and forming vertical bands in the neck. These diverging bands are apparent in repose but become more noticeable during animated conservation.

### Botox and brow lift {#sec3-8}

The Botox-assisted brow lift has been shown to provide stable, long-lasting, esthetic results with minimal morbidity.\[[@ref14]\] Brow lifts may have an unpredictable cosmetic outcome based on postsurgical healing. It is important to stabilize brow musculature for a predictable final brow position.

### Botox and laser resurfacing {#sec3-9}

In general, lasers address static wrinkles and cause stimulation of new collagen, whereas Botox cause prevention of the recurrence of dynamic wrinkles.\[[@ref15][@ref16][@ref17]\] Better results can be produced by giving Botox injection 2--3 weeks before laser resurfacing.\[[@ref16]\]

### Botox and peels {#sec3-10}

Botox should be done 2--3 days before chemical peels, otherwise if done immediately before or after peels it can cause soft tissue swelling and increased migration of the toxin.\[[@ref18]\]

### Botox and fillers {#sec3-11}

Botox may decrease the amount of fillers required for lines. Botox treatment 2--4 weeks prior to fillers softens the muscle contractions and gives a more accurate idea of how much filler is required.\[[@ref18]\]

### Hyperhidrosis {#sec3-12}

It is most common to have hyperhidrosis in the axilla, palms, or soles. For all these sites, Botox has effectively decreased sweating.\[[@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\]

Management of Frey\'s syndrome and hypersialorrhea {#sec2-2}
--------------------------------------------------

Recent research interest has led to the use of BT-A to block another important autonomic dysfunction. It has been shown recently that intraglandular injection of BT-A reduces salivation in neurologically-impaired patients who have hypersialorrhea.\[[@ref25][@ref26]\]

Treatment of primary axillary hyperhidrosis {#sec2-3}
-------------------------------------------

The use of BT-A in the treatment of primary axillary hyperhidrosis is relatively recent. Similar levels of efficacy and safety are provided by both Botox and Dysport in the treatment of primary axillary hyperhidrosis in a condition in which when a conversion factor of 1:3 is used.\[[@ref27]\]

Neuromuscular correction of gummy smile {#sec2-4}
---------------------------------------

The temporary improvement of gummy smiles caused due to hyperfunctional upper lip elevator muscles by injecting BT-A at preselected sites is a novel, cosmetically effective, minimally invasive alternative.\[[@ref28][@ref29]\]

Treatment of hemimasticatory spasm {#sec2-5}
----------------------------------

Hemimasticatory spasm is a rare movement disorder caused due to trigeminal motor nerve dysfunction of unknown origin. Most often it is misdiagnosed as hemifacial spasm caused due to dysfunction of the facial nerve. A case of hemimasticatory spasm has been reported to be associated with localized scleroderma and facial hemiatrophy; and excellent results have been obtained with the use of BT-A injections.\[[@ref30]\]

Control of pain of trigeminal neuralgia {#sec2-6}
---------------------------------------

Neurological improvement seen who have received BT-A injections in the trigger zone of trigeminal neuralgia.\[[@ref31]\]

Treatment for reduction of plantar flexors spasticity after stroke {#sec2-7}
------------------------------------------------------------------

BT-A is a potent neurotoxin that blocks local synaptic transmission at cholinergic terminals. It has become a useful therapeutic alternative for spasticity management as it is safe and also effective option in the treatment of poststroke spasticity. Its principal advantage is that it has a focal, selective, and reversible effect in the injected muscles without having much adverse effects.\[[@ref32]\] BT is significantly associated with reduced spasticity, increased range of motion, and improved upper extremity function. The use of electrical stimulation in combination with BT injection improves upper extremity function. The Reduction of shoulder pain and improvement of passive range of motion is more with denervation of the subscapularis muscle using BT than denervation of the pectoralis major muscle. Denervation of lower extremity muscles by injecting BT reduces spasticity but does not improve function. A combination of BT with electrical stimulation may improve spasticity and function.\[[@ref33]\]

Treatment of cerebral palsy in children and adolescents {#sec2-8}
-------------------------------------------------------

### Reasons for considering botulinum toxin Type A as a treatment approach {#sec3-13}

The following reasons justify the use of BT-A as treatment approach in children and adolescents suffering from cerebral palsy:\[[@ref34]\]

Reduces spasticity to free up movement in the arm and handPrevents shortening of musclesImproves the appearance of the hand and armReduces pain or discomfortImproves the use of arm and handReduces the need to wear splintsThe outcome of possible surgery can be predictedThe need for surgery can be delayed.

### Steps to be taken before treatment with botulinum toxin Type A {#sec3-14}

The child is usually admitted as a day patient at hospitalInjections are given under a general anesthesia for easy and accurate injection of BT into the relevant musclesA muscle stimulator is used to make sure that BT-A is injected into the correct muscle as most of the muscles in the forearm and hand are very small and lie adjacent to each other.

### Steps to be taken after treatment with botulinum toxin Type A {#sec3-15}

Usually, the effect of the injection is within 7--10 days, some reported within 24--36 hThe occupational therapist provides an intervention or group program and keeps in touch with the child and family to monitor progress. A home activity program is also often provided. Evidence support that BT-A injections in combination with a therapy and home program help the clients to make greater gains in movement and functionThe occupational therapist reviews the child approximately 3 months following BT-A injection to determine the outcomes of the intervention.

Treatment of depression {#sec2-9}
-----------------------

Major depression is a very serious and common condition that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches. BT-A is used to treat glabellar frown lines in treating patients with major depression.\[[@ref35]\]

Treatment of masseteric hypertrophy {#sec2-10}
-----------------------------------

The diagnosis of head and neck masses reveal a rare condition called masseter muscle hypertrophy in the cheek with unknown cause. Various treatment options ranging from simple pharmacotherapy to more invasive surgical reduction have been reported. BT-A, a powerful neurotoxin produced by the anaerobic organism *C. botulinum* causes interference with the neurotransmitter mechanism when injected into a muscle and produces selective paralysis, subsequently causing muscular atrophy. Injection of BT-A into the masseter muscle is considerably a less invasive modality and often used for cosmetic sculpting of the lower face. BT-A injection is considered as a beneficial treatment modality in patients with masseter muscle hypertrophy.\[[@ref36]\]

Use in migraine surgery {#sec2-11}
-----------------------

The patients who claimed to have migraine headaches were examined by the neurologists\' team to confirm its diagnosis. After answering an extensive questionnaire, Botox (25 U) was injected in the corrugators supercilii muscle of those patients. The treatment procedure using Botox and surgery in the elimination of migraine headaches is colossal, elimination of migraine headaches following forehead rejuvenation.\[[@ref37][@ref38]\]

Use in esthetic oculoplastic surgery {#sec2-12}
------------------------------------

The facial augmentation and rejuvenation in the periocular region require medical and surgical management. Laser resurfacing such as fractional lasers, use of dermal fillers, dermabrasion, chemical peeling, and BT injections are considered as medical measures. Tissue augmentation also involves increased use of hyaluronic acid injections. Commonly practiced surgical procedures are mid face lift, browplasty, and blepharoplasty. It is safe and effective to use BT-A (Botox; Allergan, Inc.; Irvine, CA, USA) as a muscle paralytic agent for both short- and long-term durations. BT can be injected by esthetic oculoplastic clinicians either in only one area or many areas to provide maximum eyelid elevation. It should be noted that the use of BT for any area other than the glabellar frown line is off label.\[[@ref1]\]

Ocular uses {#sec2-13}
-----------

### Strabismus {#sec3-16}

When used for the treatment of strabismus, it is hypothesized that BT-A causes lengthening of the muscle in which it is injected and a corresponding shortening of the antagonist muscle.

### Entropion {#sec3-17}

BT has been used safely for the treatment of spastic and congenital entropion\[[@ref39]\] by injecting in the pretarsal portion of the orbicularis oculi muscle (5 U). Reports also suggest its use in the treatment of senile entropion\[[@ref40]\] though it is temporary and surgery remains the only choice for permanent treatment.

Treatment of dysphagia {#sec2-14}
----------------------

Many investigators have used BT to chemically denervate the muscle to allow for relaxation and passage of the food bolus. It is easy to identify the cricopharyngeus muscle lateral and posterior to the cricoid cartilage using electromyography. There is constant firing of this muscle at rest which abates at the onset of a voluntary swallow. This allows for injection even in office or in the operating room under direct laryngoscopy. Response to chemodenervation with BT can predictably be a successful surgical outcome for patients not wanting repeated injections for recurrent dysphagia.\[[@ref41]\]

Treatment of puberophonia {#sec2-15}
-------------------------

Adolescent boys and men suffering from puperophonia or mutational dysphonia can also be treated by BT injection into the cricothyroid muscles. Usually puperophonia patients speak with the higher fundamental frequency of their prepubescent years. As this disorder is primarily mediated by inappropriate psychological controls and behavior, hence the primary treatment involves a combination of speech and behavioral therapy.\[[@ref42]\]

Treatment of bilateral vocal fold paralysis {#sec2-16}
-------------------------------------------

Patients suffering from bilateral abductor vocal fold paralysis/paresis are injected with BT into the thyroarytenoid and interarytenoid muscles adductor muscles of the larynx are actually weakened by those muscles. BT injection increases the patency of airway at rest and with activity. Less dyspnea was reported by such patients after BT injections.

Thus, BT injection effectively caused the rebalancing of the position of paralyzed vocal folds to a more abducted position by weakening of the adductor muscles.\[[@ref43]\]

Treatment of parotid fistula after face lifting {#sec2-17}
-----------------------------------------------

BT-A injection causes inhibition of Ach release from the preganglionic sympathetic and cholinergic autonomic parasympathetic neurons at the secretary end of the salivary gland, in addition to inhibition of NM junction. The use of BT in the treatment of sialorrhea was first reported in 1997. The injuries to parotid duct or gland with parotid fistula are not very common are the result due to traumatic surgical conditions. Such patients reported constant leakage of serous fluid and swelling cheek after facelift surgery. Those patients had to undergo an amylase test, starch-iodine test, and sialography. About 50 units of BT was injected into the parotid gland of the patients after diagnosis of parotid fistula and were advised for facial bandage, scopolamine, and instructions were given to them to reduce the movement of temporomandibular joint. Within 2 weeks, there was a decrease in leakage volume, and symptoms subsided. There were no functional problems or other complications. Thus, it can be concluded that BT provides an effective treatment for a parotid fistula after facial surgery and should be preferred considered before invasive surgical treatment.\[[@ref44]\]

Treatment of persistent parotid sialocele drooling, salivary fistulas, and sialadenitis {#sec2-18}
---------------------------------------------------------------------------------------

BT-A acts by blocking Ach release, thereby inhibiting transmission of a nerve impulse at the secretomotor parasympathetic autonomic NM junction responsible for the secretion of saliva. The treatment of parotid sialocele is with BT-A is considered to be effective when conventional therapy fails.\[[@ref45]\] BT dependably reduces salivary secretion. In general, the effect lasts for 3--4 months. During extended follow-up intervals, side effects were not observed. Thus, local injection of BT-A into salivary glands is a dependable and side-effect-free therapeutic option in patients with drooling, salivary fistulas, and chronic sialadenitis.\[[@ref46]\]

Use on cleft lip revision surgery scar {#sec2-19}
--------------------------------------

When BT-A (Botox) is injected immediately after suturing, it causes local paralysis of the musculature which lies below the surgical wound. This helps in reducing the repetitive tensile forces on the skin wound edges. This results in a decreased fibroblastic response and subsequent hypertrophic scar formation.\[[@ref47]\]

Treatment of disorders of autonomic nervous system {#sec2-20}
--------------------------------------------------

BT-A has become an important method of treatment of neurological disorders and other disorders associated with Ach such as excessive muscular contraction and glandular hypersecretion. It is one of the most potent neurotoxin which has been effective in many fields for the past 20 years. Thus, autonomic nervous system disorders such as Frey\'s syndrome, sialorrhea, hyperhidrosis, and hyperlacrimation involving excessive activity can be treated by BT injections in cholinergic autonomic parasympathetic and postganglionic nerve synapses.\[[@ref48]\]

C[ontraindications of]{.smallcaps} B[otulinum]{.smallcaps} T[oxin]{.smallcaps} {#sec1-6}
==============================================================================

The following conditions should be avoided for treatments with BT:\[[@ref49]\]

Patients who have known NM disorders or sensitivity to the ingredients in the formulationDuring pregnancy or nursingDrugs such as calcium channel blockers, quinine, or aminoglycoside antibiotics increase the potency of BT; patients already taking these medications should be treated cautiouslyPatients having previous surgical procedures at the same site as BT injection site which was repositioned or weakened the muscle of interest should be considered as suboptimal candidatesAllergic to BT and its components (i.e., BT, human albumin, saline, lactose, and sodium succinate)Dependent on intact and active movements of facial muscles and expressions on the faces for their living (e.g., musicians, singers, actors, and other media personalities).

G[eneral]{.smallcaps} P[recautions]{.smallcaps} {#sec1-7}
===============================================

When treatment with BT-A is selected as a therapeutic approach following precautions should be taken into consideration:\[[@ref50]\]

The use of aminoglycoside antibiotics or drugs interfering with NM transmission (e.g., tubocurarine-type muscle relaxants) can usually potentiate the effect of BT. Therefore, a detailed drug history should be elicited before injection of the toxinPrecautions should be taken when BT-A is utilized for the treatment of disorders such as myasthenia gravis, Eaton-Lambert Syndrome, and others which produce a depletion of AchThere is the possibility of anaphylactic reaction as occurs with all biologic products. Necessary precautions should be taken and epinephrine should be availableNo data is available on the use of BT-A in pregnant women or of its excretion in human milk. Therefore, one should be cautious about the use of BT in pregnant and lactating womenIt is not established to be safe for use in children under 12 years of agePatients with BT administration should resume activity gradually.

C[onclusion]{.smallcaps} {#sec1-8}
========================

Scientific research into the established serotype of BT-A as well as others has continued to provide important clinical information about the proper use of this neurotoxin. Nowadays, while BT-A remains the mainstay for clinical therapy, BT Type B has gained importance in the treatment of patients having acquired antibody resistance to BT-A. However, further research is required to define morphological alterations in the BT-injected injected tissues, its duration of action, the formation of neutralizing antibody, and the development of possible long-term effects. All the authors of this manuscript hope that this article has provided interesting background information for the clinician and an informative literature for understanding the clinical role of BT to improve delivery of patient care.
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